Immutep has announced topline results from the trial evaluating its eftilagimod alfa in combination with MSD’s anti-PD-1 therapy KEYTRUDA (pembrolizumab) as first-line treatment of recurrent and metastatic head and neck squamous cell carcinoma. …
Australian company reports topline results from clinical trial involving MSD's Keytruda
June 28, 2024 Latest NewsAustralian Biotech
Latest Video
New Stories
-
Who remembers the 'Vancouver' poster? We have a rerun
September 22, 2026 - - Latest News -
If there is a productivity gain in the process, then it should be passed on
September 22, 2026 - - Latest News -
Given the official use of AI, a cease and desist would not be unreasonable
September 22, 2026 - - Latest News -
Treasury has moved on from the PBS, but the policies built on its error have not
September 21, 2026 - - Latest News -
Nyrada banks $12 million as directors contribute in nearly half
September 21, 2026 - - Australian Biotech -
Telix announces takeover of ITM to create a global radiopharmaceutical powerhouse
September 21, 2026 - - Australian Biotech -
Only 2 per cent of Australians can name the signs of a heart condition behind one in four strokes
September 21, 2026 - - Latest News